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Sunmary Around 60% of oral squamous cell carcinomas (SCCs) have been shown to harbour p53 muta-
tions. and other studies have demonstrated mutant p53 genes in normal and dysplastic squamous epithelium
adjacent to these SCCs. In line with these earlier studies we show here that DOK, a keratinocyte cell line
derived from a dysplasia. displays elevated levels of p53 protein and harbours a 12 bp in-frame deletion of the
p53 gene spanning codons 188-191. In contrast, the coding region of the p53 gene was normal in a series of
six benign recurrent laryngeal papillomas and a series of four premalignant oral erythroplakia biopsies and
their cell cultures. All but one of these lesions were free of malignancy at the time of biopsy, in contrast to the
premalignant lesions studied by previous investigators, but keratinocytes cultured from these lesions all
displayed a partially transformed phenotype that was less pronounced than that of DOK. Since three out of
four of the erythroplakia patients developed SCC within 1 year of biopsy. these lesions were by definition
premalignant. The availability of strains of partially transformed keratinocytes from premalignant erythro-
plakias which possess normal p53 genes should enable us to test the role of mutant p53 in the progression of
erythroplakia to SCC. The premalignant tissues and cultures were also tested for the presence of human
papillomavirus (HPV). which is known to inactivate p53 function in some cases. Only the benign papillomas
were shown to contain high levels of either HPV 6 or HPV II E6 DNA. but not both. and none of the
samples contained detectable levels of HPV 16. HPV 18 or HPV 33 E6 DNA or LI DNA of several other
HPV types. There was therefore no eVidence to suggest that p53 was being inactivated by a highly oncogenic
HPV in these samples.
Squamous cell carcinoma of the head and neck (SCC-HN) is
an extremely common tumour worldwide (Pindborg, 1984;
Million et al.. 1989). yet little is known of the molecular
mechanisms which result in its development. Some SCC-HN
arise from premalignant lesions such as papillomas, leuko-
plakias and erythroplakias. while others do not. Papillomas
in humans are essentially benign, with only a small percen-
tage (less than 1%) progressing to malignancy, but leuko-
plakias and more usually erythroplakias do progress to
malignancy (Pindborg, 1985).
The p53 tumour-suppressor gene has been implicated in
the pathogenesis of SCC-HN and is commonly mutated or
deleted in tumours from Caucasian populations (Brachman
et al., 1992; Jung et al., 1992; Maestro et al., 1992; Somers et
al.. 1992; Boyle et al., 1993; Burns et al., 1993; Chung et al.,
1993; Nees et al.. 1993). In many cases this leads to stabilisa-
tion of the p53 protein, rendering it unusually detectable by
immunocytochemistry (Field et al., 1991; Gusterson et al.,
1991; Maestro et al., 1992; Burns et al., 1993). Elevated levels
of p53 protein have also been reported in histologically nor-
mal oral mucosa and dysplastic tissue adjacent to SCCs of
the oral cavity (Gusterson et al.. 1991; Ogden et al., 1992)
and larynx (Dolcetti et al., 1992) and also in the more basal
cells of recurrent (Clark et al., 1993a) but not solitary (Ogden
et al.. 1992) laryngeal papillomas. This has led some authors
to speculate that mutation of p53 might be an early event in
the development of SCC-HN (Dolcetti et al.. 1992). and very
recently it has been shown that at least in some instances
both histologically normal (Nees et al., 1993) and dysplastic
(Boyle et al.. 1993) oral epithelia harbour mutant p53 genes.
Most of these mutants. however, are likely to be of the stable
(Oren et al.. 1981) and possibly gain-of-function type (Halevy
et al.. 1990) since they result in increased levels of p53
protein (Dolcetti et al.. 1992; Nees et al.. 1993). It is less
certain whether loss of p53 suppressor function can influence
squamous neoplasia at such an early stage. since in mouse
multistage SCC development p53 loss appears to influence
only the later stages of progression to carcinoma (Kemp et
al.. 1993).
The p53 protein has also been shown to be targeted for
degradation by the E6 protein of the more oncogenic human
papillomaviruses (HPV; Scheffner et al., 1990; Werness et al..
1990) and by some investigators to be complexed, but not
degraded, by the E6 proteins of the less oncogenic HPV types
6 or 11 (Crook et al.. 1991). HPV types 2 (de Villiers et al..
1985; Adler-Storthz et al., 1986), 4 (Yeudall & Campo, 1991).
16 (Maitland et al.. 1987. 1989; Yeudall & Campo. 1991;
Brachman et al., 1992). 18 (Yeudall & Campo, 1991) and 33
(Snijders et al., 1992) have been reported from malignant
SCC-HN. types 6 and 11 from recurrent laryngeal papillomas
(Gissman et al., 1982; Mounts et al., 1982) and types 16 and
18 from papillomas, leukoplakias, dysplasias, keratoses and
lichen planus (Loning et al., 1985; Maitland et al.. 1987).
In order to understand further the molecular events which
give rise to premalignant head and neck lesions and influence
their progression, we have examined the p53 and HPV status
of several of these neoplasms and the phenotypically charac-
terised cultures derived from them.
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Tissue collection andpathologv
Tissues, cell cultures and the cell line DOK together with
their properties are all listed in Table I. The six adult recur-
rent papilloma samples (Clark et al., 1993a), the four eryth-
roplakia cultures (Edington et al., 1994) and the cell line
DOK (Chang et al., 1992) have all been described
previously.
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Cultivation andproperties of the premalignant keratinocvtes
The human papilloma (BICR P2. BICR P5) and erythro-
plakia (BICR El. BICR E2. BICR E4. BICR ES) keratino-
cvtes were cultured on lethally irradiated Swiss 3T3 feeder
cells in Dulbecco's modified Eagle medium. 20% (v v) fetal
bovine serum. 0.4 g ml-' hydrocortisone and 10 ng ml-
cholera toxin as descnrbed previously (Edington et al.. 1994).
DOK cells were cultured in the same wax except that 10o
(v v) fetal bovine serum was used and cholera toxin was
omitted. The properties of the cells are listed in Table II. The
DOK and erythroplakia cultures are known to be composed
of transformed keratinocytes since all of these cultures con-
tain low levels of terminally differentiated cells as assessed by
cross-linked cornified envelope formation (Table I. Edington
et al.. 1994). Furthermore. all of these cultures show a low
tendency to terminally differentiate when their proliferation is
arrested in suspension culture (Edington et al.. 1994). Both
the papilloma and the erythroplakia cells are diploid. have a
limited culture lifespan which is not necessarily longer than
normal tongue keratinocytes from adults of the same age
group and require essentially the same culture conditions as
normal keratinocytes for optimal proliferation. DOK cells
possess additional abnormalities in that they are aneuploid.
possess an unlimited culture lifespan and have a reduced
requirement for serum growth factors and cholera toxin.
DOK is therefore phenotypically more abnormal than the
other keratinocv-tes studied.
Detection ofhuman papilloma virus DNA bY polvmerase chain
reaction (PCR)
The detection of HPV E6 DNA was performed essentially as
described by Burns et al. (1993) using SiHa as a positive
control for a single copy of HPV 16 DNA per cell and HeLa
as a control for HPV 18. SiHa contains only one copy of
Table I Premalignant tissues used in the study
Tissue Culture Pathologi MalignancY present
Papillomas
BICR PI No Papilloma No
BICR P2 Yes Papilloma No
BICR P3 No Papilloma No
BICR P4 No Papilloma No
BICR P5 Yes Papilloma No
BICR P6 No Papilloma No
Erlvthroplakias`;
BICR El Yes Carcinoma in situ No
BICR E2 Yes Carcinoma in situ Yes'
BICR E3 No Dvsplasia Yes'
BICR E4 Yes Carcinoma in situ Yes5
BICR E5 Yes Severe dysplasia Yes'
Erithematous leukoplakia'
DOK Yes Severe dysplasia Yes'
Data from Edington et al. (1994). 'Malignancv present
subsequent to the biopsy being taken. 'Malignancy present at the
time of the biopsy. d Data from Chang et al. (1992).
HPV 16 DNA per cell. and HeLa cells contain 20-100 copies
of HPV 18 DNA per cell. However, when the HeLa DNA
was diluted 20-fold with normal DNA a signal was still
readily detectable, indicating that the HPV 18 detection was
sensitive at the level of 1-5 copies of HPV 18 DNA per cell.
HPRT pnrmers were used as a control for DNA integrity and
PCR efficiency. The primers used to detect the E6 DNA of
HPV types 6. 11. 16. 18 and 33 have been described previ-
ously (Arends et al.. 1989). In some cases PCR products were
deposited on nylon filters and probed for HPV sequences as
described by Yeudall and Campo (1991). The samples were
also screened for the L1 consensus region of HPV types 1. 5.
6. 11. 16. 18. 26. 27. 31. 33, 35. 39. 40. 41, 42, 45, 47. 48. 51.
52. 53. 54. 55. 57 and 59 by the method of Ting and Manos
(1990) using the Perkin Elmer Cetus HPV PCR kit and using
globin primers to test DNA integrity. These LI primers also
detect at least another 25 types of HPV which are as yet
unidentified.
Immunocwtochemistrv
Cell cultures and tissue sections were fixed and stained to
detect the p53 monoclonal antibodies PAb 240. PAb 1620
(Ball et al., 1984; Milner et al.. 1987; Gannon et al., 1990)
and PAb 1801 (Banks et al.. 1986) exactly as described
previously (Burns et al.. 1993). Human diploid fibroblasts
and human HT29 colon carcinoma cells were used as nega-
tive and positive controls respectively. Photographs were
taken under bright-field optics using a green filter. Antibodies
were obtained from Cambridge Biosciences. Cambridge.
UK.
Direct sequencing ofp53
Direct sequencing of the coding region of the human p53
gene in all samples was accomplished by PCR after reverse
transcription of RNA or direct PCR of genomic DNA
exactly as described by Burns et al. (1993).
Results
The status ofthe p53 tumour-suppressor gene in premalignant
tissues and cells
The p53 coding region was sequenced across exons 5-9 for
all six papilloma biopsies and for the cell line DOK since all
p53 mutations reported in SCC-HN have so far occurred
within this region (Brachman et al.. 1992; Jung et al.. 1992;
Maestro et al.. 1992; Sakai & Tsuchida, 1992; Somers et al..
1992; Boyle et al., 1993; Burns et al., 1993; Chung et al..
1993; Nees et al.. 1993). The four erythroplakia cultures were
sequenced across their entire coding region (Table III). No
p53 mutations were found in any of the samples or cultures
with the exception of the cell line DOK (Table III). which
harboured a 12 bp in-frame deletion of codons 188- 191
inclusive (Figure 1). We performed direct sequencing of the
reverse-transcribed RNA of DOK. but no expression of the
Table 11 Properties of the keratinocyte cultures and lines used in the study
Abnormal terminal Senescent Reduced growth
Keratinoc tes Ploidv status maturation immortal factor requirements Tumorigenicitv
Papillonias
BICR P2 Diploid ND Senescent No ND
BICR P5 Diploid ND Senescent No ND
Er throplakia-'
BICR El ND Yes Senescent No ND
BICR E2 ND Yes Senescent No ND
BICR E4 Diploid Yes Senescent No No
BICR E5 Diploid Yes Senescent No No
Ervthematous leukoplakias'
DOK Aneuploid Yes Immortal Yes No
-Data from Edington et al. (submitted). bData from Chang et al. (1992). ND. not determined.p53 IN PREMALIGNANT KERATINOCYTES 593
Table In The p53 status of premalignant keratinocytes and
tissues
Codons HPV Analysed
Keratinocv-tes p53 mutation sequenced present type in vitro
Papillomas
BICR PI Normal 126-331 HPV 11 No
BICR P2 Normal 126-331 HPV 6 Yes
BICR P3 Normal 126-331 HPV 11 No
BICR P4 Normal 126-331 HPV 6 No
BICR P5 Normal 126-331 HPV 11 Yes
BICR P6 Normal 126-331 HPV 6 No
Ervthroplakias
BICR El Normal 1-393 None Yes
BICR E2 Normal 1 -393 None Yes
BICR E3 ND ND None No
BICR E4 Normal 1-393 None Yes
BICR E5 Normal 1 -393 None Yes
ErYthroleukoplakia
DOK 12 bp deletion of 2-96 None Yes
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Figure I The 12 bp deletion in DOK cells. The figure shows the
sequence of DOK cells aligned with the sequence of another cell
line, BICR 56. which is normal in this region (Burns et alt. 1993).
The 12 bp deleted in DOK spanning codons 188-191 is indicated
by the bracket on the sequence of BICR 56.
normal p53 allele was detectable, suggesting that the normal
allele had been lost or that its expression had been sup-
pressed by some other mechanism.
The 12 bp deletion in the DOK cell line appeared to result
in the stabilisation of the p53 protein since it was readily
detectable by both PAb 1801 (Figure 2a) and PAb 240
(Figure 2b) antibodies followed by immunoperoxidase stain-
ing. Antibody PAb 1620, which does not recognise fixed or
mutant p53, gave only weak background staining (Figure 2c),
a b
d
Fgre 2 Immunostaining of DOK cells with anti-p53 mono-
clonal antibodies. a. PAb 1801. b. PAb 240. c. PAb 1620. d. No
antibody (control).
and no staining was seen when the primary antibodies were
omitted (Figure 2d). Previously it was reported that DOK
cells do not react strongly with PAb 240 and PAb 1801
(Chang et al.. 1992). but a suboptimal fixation protocol for
staining p53 in keratinocytes was employed in the earlier
study (see Gusterson et al.. 1991). The erythroplakia and
papilloma cultures all produced a staining pattern with the
p53 antibodies which was indistinguishable from normal
keratinocytes (data not shown). Also. sections of the erythro-
plakia biopsy BICR E5 showed no evidence of p53 immuno-
reactivity when tissue sections of this sample were reacted
with antibody PAb 1801 (data not shown).
These results suggest that. with the exception of the cell
line DOK none of the premalignant tissues and cultures
studied here contain significant numbers of keratinocytes
harbouring p53 mutations. since the direct sequencing
method is capable of detecting a mutation when only
10-15% of the cells in a sample contain it (Clark et al..
1993b).
Detection ofhuman papillomavirus tipes in premalignant
squamous tissues and cell
Since several HPV types are known to infect the upper
aerodigestive tract and the E6 proteins of some of these types
have been proposed to inactivate p53 (Scheffner et al., 1990;
Werness et al.. 1990; Crook et al.. 1991). we screened for the
presence of HPV in our samples. Figure 3 shows the detec-
tion of the E6 DNA of either HPV types 6 or 11 in each of
six adult recurrent human laryngeal papillomas. All the
papillomas contained either the E6 DNA of HPV type 6 or
11 but never both (Table III). None of the erythroplakia
tissues. their cell cultures or the cell line DOK contained
detectable HPV type 6 or 11 E6 DNA (Table III).
It is still unclear how mutation of the p53 tumour-suppressor
gene influences the development and progression of SCC-
HN. There is evidence that mutations of the p53 gene which
lead to stabilisation of the protein give keratinocytes a selec-
tive advantage at an early stage of SCC development (Gus-
terson et al., 1991; Dolcetti et al.. 1992; Ogden et al.. 1992;
Nees et al.. 1993). and it is possible that these mutants are of
the gain-of-function transforming class (Halevy et al.. 1990).
However, experiments using p53 null mice and their
heterozygotes suggest that mere loss of p53 function
influences only progression from the premalignant to the
malignant state during progression to SCC (Kemp et al..
1993). Furthermore, some SCC-HN do not possess p53
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Figure 3 Detection of HPV types 6 and 11 in human recurrent
papillomas. Lane 1. molecular weight markers; lanes 2-7. HPV 6
pnmers: lanes 8-13. HPV 11 pnrmers: lane 14. kit control. BICR
P1. lanes 2 and 8: BICR P2. lanes 3 and 9: BICR P3. lanes 4 and
10: BICR P4. lanes 5 and I1; BICR P5. lanes 6 and 12: BICR P6.
lanes 7 and 13; A = 236 bp HPV fragment. Top arrow = gel top.
Bottom arrow = gel bottom.
mutations at all. even at a late stage of tumour progression.
and these same tumours lack detectable HPV (Brachman et
al., 1992). Therefore. there may be SCCs which arise by a
mechanism in which p53 dysfunction cannot bestow a selec-
tive advantage on the developing tumour cells until a very
late stage. if at all. Therefore. premalignant human oral
keratinocyte cultures which lack both p53 mutation and
oncogenic HPV types would be useful to test the role of p53
dysfunction in progression towards SCC. In this paper we
have tested several human premalignant cultures to identify
such cultures.
Six laryngeal papillomas and two of their cell cultures were
shown to have normal p53 genes spanning codons 126-331
(Table III). but all of them harboured either HPV 6 or HPV
11 E6 sequences (Figure 3. Table III). Since it has been
reported that the E6 protein of HPV types 6 or 11 binds p53
in vitro (Crook et al.. 1991). it is possible that the presence of
these viruses partially inactivates the p53 protein in these
cells and may explain the unusually high levels of p53 protein
found in the more basal layers of recurrent papillomas in vivo
which we reported previously (Clark et al.. 1993a). Therefore,
cultures of laryngeal papilloma cells would not be ideal
materal to investigate the role of p53 in progression to SCC
as they could not be guaranteed to possess a normal-func-
tioning p53 protein.
We also investigated the p53 status of five premalignant
keratinocyte cultures which were isolated from either
squamous dysplasias or carcinomas in situ (Table I). None
contained detectable oncogenic HPV E6 or L1 DNA se-
quences (Table III) so there was no evidence to support the
inactivation of p53 by these viruses. The cell line DOK
(Chang et al.. 1992) did. however, possess a homozygous
12 bp deletion of the p53 coding region (Figure 1 and Table
III) and expressed elevated levels of the p53 protein (Figure
2a and b). Since DOK was isolated from dysplastic epi-
thelium adjacent to an SCC of the tongue (Chang et al.,
1992) and the presence of p53 mutations has been reported
from such lesions (Boyle et al.. 1993). it is not surprising that
this cell line harbours a p53 mutation. Nevertheless, since
DOK is non-tumorigenic (Chang et al.. 1992) it should be
useful in the study or identification of mutations which
cooperate with mutant p53 to effect progression towards
SCC.
In contrast, all of the keratinocyte strains derived from
premalignant oral erythroplakias lacked a p53 mutation in
the coding sequence, and at least two (BICR E4 and BICR
E5) have not lost heterozygosity at the p53 locus (Edington
et al., 1994). making a mutation outside the coding sequence
also unlikely. We have considered several possibilities to
explain our results. First. the erythroplakia keratinocytes
might be in fact be normal cells since they have diploid
karyotypes and senesce in culture (Table II). However, all
four BICR keratinocyte strains from erythroplakias showed a
reduced rate of terminal maturation when placed in suspen-
sion culture (Edington et al.. 1994, Table II) and did not
proliferate when placed in serum-free MCDB 153 medium
(Wille et al., 1984), which supports extensive proliferation of
normal keratinocytes (Edington et al., 1994). Second. the
erythroplakia cell might be benign, not premalignant; how-
ever, this is also unlikely as BICR E5 already contained a
developing carcinoma at the time of biopsy and patients
BICR E2 and BICR E4 developed SCC within 12 months of
the original biopsy date.
It is clear that DOK cells are phenotypically more altered
than the erythroplakia cells (Table II) and in addition are
aneuploid (Chang et al., 1992) and express high numbers of
epidermal growth factor receptors (Stanton et al.. 1994). This
is not surprising in view of the evidence that one of the
functions of p53 is to maintain genetic stability (Bischoff et
al.. 1990; Kastan et al., 1991; Lane, 1992; Livingstone et al.,
1992; Yin et al., 1992) and the data showing that DOK cells
possess a homozygous deletion within the p53 gene.
It is, however, still uncertain whether the erythroplakia
keratinocytes are at an earlier stage of tumour progression
than DOK or whether they represent the precursor lesion of
a type of SCC-HN which arises by a p53-independent
mechanism. The availability of a series of premalignant
erythroplakia keratinocytes which possess normal p53 genes
now permits us to address these questions by manipulating
the p53 status of these cells.
The authors would like to thank Professor John Wyke for critical
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